https://www.selleckchem.com/pr....oducts/Temsirolimus.
3 months. Patients with symptomatic RN had a larger mean target volume (p0.0001), and thus larger V100% (p0.0001), V50% (p0.0001), V12Gy (p0.0001), and V10Gy (p=0.0002), compared to the rest of the cohort. Single-fraction treatment (p=0.0025) and diabetes (p=0.019) were also significantly associated with symptomatic RN. SRS is an effective treatment option for patients with brain metastases; however, a subset of patients may develop symptomatic RN. We found that patients with larger tumor size, larger plan V100%, V5
Like
Comment
Share
